指南与共识类风湿关节炎脊柱关节炎其他结缔组织病

抗风湿药物在生育、妊娠和哺乳期的应用:为2024年EULAR推荐更新提供依据的系统文献综述

Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations.
指南 / 共识 · Ann Rheum Dis · 2025-04-16

本研究通过系统文献综述(筛选6680篇,纳入255篇)更新抗风湿药物在生育、妊娠和哺乳期的安全性证据。Meta分析未发现TNFi与不良妊娠结局或婴儿严重感染相关,口服糖皮质激素呈剂量依赖性早产风险增加,非甾体抗炎药可逆性降低生育力,环磷酰胺是唯一导致剂量依赖性不可逆不育的药物。

要点

  • TNFi暴露未增加不良妊娠结局或婴儿严重感染风险,非TNFi生物制剂数据未引起担忧。
  • 口服糖皮质激素与早产风险呈剂量依赖性关联,非甾体抗炎药可逆性降低生育力。
  • 环磷酰胺是唯一导致剂量依赖性不可逆不育的药物,男性甲氨蝶呤等未显示不良影响。

核心结论

  • 本系统文献综述为2024年EULAR关于抗风湿药物在生育、妊娠和哺乳期使用的推荐更新提供了最新证据。

研究设计与样本

  • 系统文献综述,检索生殖、不良妊娠结局和哺乳相关关键词,筛选6680篇文章,最终纳入255篇。
  • 男性药物安全性基于两篇已评价的系统文献综述;数据充足时对母亲药物暴露与不良妊娠结局风险进行Meta分析。

主要发现

  • 妊娠期证据多集中于生物制剂改善病情抗风湿药(bDMARDs),采用校正风险估计的Meta分析未发现TNFi使用与不良妊娠结局或婴儿严重感染相关。
  • 非TNFi bDMARDs数据未引起担忧;bDMARD暴露婴儿对轮状病毒活疫苗接种未报告严重不良事件。
  • TNFi暴露婴儿在出生后前6个月内接种卡介苗的安全性可能值得关注。
  • 口服糖皮质激素的系统文献综述和采用校正风险估计的Meta分析发现其与早产风险增加呈剂量依赖性关联。
  • 非甾体抗炎药使用可逆性降低生育力;哺乳期各种bDMARDs的现有数据令人安心。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to summarise and update evidence to inform the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation. METHODS: A systematic literature review (SLR) was performed, including keywords on reproduction, adverse pregnancy outcomes (APOs), and lactation. Two appraised SLRs were the basis for the SLR on drug safety in men. If sufficient data were available, a meta-analysis was performed on maternal drug exposure and the risk of APOs. RESULTS: Of 6680 screened articles, 255 were included in the final analysis. In pregnancy, most evidence was available for biologic disease-modifying antirheumatic drugs (bDMARDs). Meta-analyses with adjusted risk estimates did not reveal APOs or serious infant infections to be associated with tumour necrosis factor inhibitor (TNFi) use. Data on non-TNFi bDMARDs did not raise concerns. In bDMARD-exposed infants, no serious adverse effects to rotavirus live vaccination were reported. Safety of Bacille Calmette-Guérin vaccination in TNFi-exposed infants could be a concern in the first 6 months of life. Regarding oral glucocorticoids, the SLR and meta-analysis using adjusted risk estimates found a dose-dependent association with an increased risk of preterm birth. Nonsteroidal anti-inflammatory drug use could reversibly reduce fecundability. Concerning lactation, available data on various bDMARDs was reassuring. In male patients, available evidence on methotrexate and most other drugs did not reveal adverse effects on sperm quality or birth outcomes. Cyclophosphamide remains the only drug that causes a dose-dependent irreversible infertility. CONCLUSIONS: This SLR provides up-to-date evidence to guide the 2024 update of the European Alliance of Associations for Rheumatology recommendations for the use of antirheumatic drugs in reproduction, pregnancy, and lactation.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Pluma A, Hamroun S, Rüegg L, et al. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis. 2025. PMID: 40240264. doi:10.1016/j.ard.2025.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。